PAVmed Highlights First-In-Human Implantations of its PortIO Infusion System - PAVmed (NASDAQ:PAVM)

PAVmed Inc PAVM announced the successful implantation of its PortIO Intraosseous Infusion System in three patients as part of a first-in-human (FIH) clinical study of up to 40 patients.
No complications have occurred. "This is a groundbreaking milestone in the field of vascular access," said implanting interventional radiologist, Dr. David Sabbag.
PortIO is an implantable intraosseous vascular access device designed for long-term use and to eliminate many of the shortcomings of existing vascular access devices, including the need for regular flushing to maintain patency.
The PortIO Intraosseous Infusion System consists of an implantable intraosseous vascular access device and insertion kit.
PortIO can be inserted and removed near-percutaneously without requiring a surgical pocket or significant dissection and does not require confirmation of the position of the tip by x-ray or other means.
Price Action: PAVM shares are up 25.4% at $1.58 during the market session on the last check Thursday.